A Randomized, Double-Blind, Placebo Controlled, Single-Dose Study to Assess the Initial Efficacy of Canakinumab (ACZ885) With Respect to the Adapted ACR Pediatric 30 Criteria in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations.

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Single-Dose Study to Assess the Initial Efficacy of Canakinumab (ACZ885) With Respect to the Adapted ACR Pediatric 30 Criteria in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2018

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms Beta-SPECIFIC-1
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 02 Mar 2018 Results pooled data from four SJIA studies (NCT00426218, NCT00886769, NCT00889863, NCT00891046), were published in the Clinical and Experimental Rheumatology.
    • 08 Nov 2017 Results of pooled data from four SJIA studies (NCT00426218, NCT00886769, NCT00889863, NCT00891046) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 17 Jun 2017 Results of pooled analysis (NCT00426218, NCT00886769, NCT00889863, NCT00891046) presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top